Effect of ketofol on persistent pain in patients with cancer that has spread to the bone

The analgesic effect of ketofol on intractable pain in cancer patients with bone metastasis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN00353297

Enrollment

Registered

2013-11-21

Start date

2009-12-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intractable pain in cancer patients with bone metastasis Cancer

Interventions

Based on the dosage of ketamine, propofol and ketofol for the sedation and/or analgesia in the previous studies, we conducted a preliminary study on 20 cancer patients with intractable pain to determi

the concentration of both ketamine and propofol was 1 mgml per min.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Intractable cancer pain caused by bone metastasis 2. Age 18 years or over 3. Recent use of the fentanyl patch 4. Duration of pain being 4 weeks or longer 5. Visual analog scale (VAS) pain intensity score during the previous week = 5 cm (on a scale of 0-10 cm)

Exclusion criteria

Exclusion criteria: We excluded the patients with a confirmed or suspected allergy to intravenous fat emulsion, propofol or ketamine

Design outcomes

Primary

Measure	Time frame
1. VAS scores were recorded at baseline (after first morphine titration), 1 h, 3 h, 6 h, 12 h, 24 h and 48 h 2. Cumulative morphine consumption (CMC) was recorded at 1 h, 3 h, 6 h, 12 h, 24 h and 48 h after the start of the drugs infusion	—

Secondary

Measure	Time frame
1. Age, gender, weight, height, underlying disease, length of stay in hospital (LOS) measured at baseline 2. Vital status at hospital was evaluated at one month 3. Simplified acute physiology score III (SAPS III) points, and SAPS III predicted mortality (%) were recorded at baseline 4. Heart rate (HR) and mean arterial pressure (MAP) were recorded by an independent investigator at baseline, 5 min, 15 min, 30 min, 1 h, 3 h, 6 h, 12 h, 24 h and 48 h 5. Side effects including nausea, vomiting, hallucination, double vision, dreaming and nightmares were recorded at 48 hours	—

Measure

Time frame

1. Age, gender, weight, height, underlying disease, length of stay in hospital (LOS) measured at baseline 2. Vital status at hospital was evaluated at one month 3. Simplified acute physiology score III (SAPS III) points, and SAPS III predicted mortality (%) were recorded at baseline 4. Heart rate (HR) and mean arterial pressure (MAP) were recorded by an independent investigator at baseline, 5 min, 15 min, 30 min, 1 h, 3 h, 6 h, 12 h, 24 h and 48 h 5. Side effects including nausea, vomiting, hallucination, double vision, dreaming and nightmares were recorded at 48 hours

—

Countries

Turkey

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026